Hemogenyx Pharmaceuticals has picked LakePharma as its service provider for the development and manufacturing of Hemogenyx’s lead product, CDX bi-specific antibodies, as it believes that CDX bi-specific antibodies could replace traditional methods of conditioning patients for bone marrow transplants-eliminating the need for pre-transplantation chemotherapy and radiation, which can damage a patient’s health-and allow more patients to benefit from the curative power of bone marrow transplants.
The relationship between Hemogenyx Pharmaceuticals and LakePharma should go through discovery to biomanufacturing. Strategically, this relationship is particularly significant because it marks a major step in the pre-clinical development of Hemogenyx’s CDX antibodies, Hemogenyx. Furthermore, with the expertise and validated technology of LakePharma, the largest US-based biologics contract research organization, this step brings Hemogenyx significantly closer to its goal of taking the CDX antibodies into clinical trials at the earliest opportunity with a faster path through pre-clinical trials.
Dr. Vladislav Sandler, CEO of Hemogenyx, said: “After a thorough evaluation process, we chose to partner with LakePharma for the development and manufacture of CDX antibodies for preclinical tests. The speed, quality and sophistication of LakePharma’s services gives us confidence that we will go into clinical trials on time with a reliable product that will eventually save lives.”
Dr. Hua Tu, Founder and CEO of LakePharma, said: “LakePharma has been providing antibody engineering and bioproduction service to Hemogenyx for several years and helped them to create the underlying IP for their CDX technology. We are pleased to see that LakePharma’s one-stop-shop capabilities can be applied towards Hemogenyx’s breakthrough product development.”